Pervasis Therapeutics Presents Data at American Society of Nephrology Meeting

Pervasis Therapeutics Presents Safety Data from Phase 1 and 2 Clinical Trials of Vascugel® at the American Society of Nephrology Annual Meeting New clinical data show excellent safety profile for novel therapy that may promote natural healing and regeneration of the vasculature in dialysis patients needing permanent AV access CAMBRIDGE, Mass. – November 6, 2008 – Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, today announced new data from Phase 1 and 2 clinical trials of Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature. Data from these trials indicate that Vascugel® has an excellent safety profile in patients with end-stage renal disease (ESRD) that need... [read full story]